pyrazinamide
pyrazinamide.JPG

CLINICAL USE

Antimicrobial agent for tuberculosis

DOSE IN NORMAL RENAL FUNCTION

1.5–2 g per day

PHARMACOKINETICS

  • Molecular weight                           :123.1
  • %Protein binding                           :10
  • %Excreted unchanged in urine     : 4
  • Volume of distribution (L/kg)       :0.75–1.3
  • half-life – normal/ESRD (hrs)      :9–10/26

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Use 50–100% of dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR <10 mL/min
  • HD                     :50–100% dialysed. Dose as in GFR <10 mL/min or 25–30 mg/kg post dialysis1
  • HDF/high flux   :Dialysed. Dose as in GFR
  • <10           : mL/min or 25–30 mg/kg post dialysis1
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Ciclosporin: on limited evidence, pyrazinamide appears to reduce ciclosporin levels

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Available from IDIS on a named patient basis. Can precipitate gout as impairs urate excretion



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs